Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 14 /PRNewswire/ -- Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. Aptuit is focused on growing its business across the drug development continuum through several areas including customer service, scientific excellence, and exceptional talent.

To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/aptuit/42018/

(Photo: http://www.newscom.com/cgi-bin/prnh/20100114/MM37675 )

"The complexities of drug development are driving the need for integrated development organizations that provide exceptional pharmaceutical services, delivered on time, in full and at a best-in-class cost," stated Timothy C. Tyson, chairman and chief executive officer at Aptuit. "We are committed to helping companies tackle some of today's toughest challenges with the ultimate goal of enhancing drug development productivity and increasing the flow of products to the market for our clients."

Mr. Tyson's presentation, to be delivered on Thursday, January 14, 2010, at 11:30 a.m., outlines Aptuit's strategy, business objectives, strength of financial position, and differentiated business model as an integrated drug development organization. The company's priorities for 2010 are focused on the following three core areas:

Demonstrated Commitment to Scientific Excellence

• Continuing to advance the company's world-class centers of excellence for solid-state chemistry and active pharmaceutical ingredient development
• Enhancing proven integrated programs such as Aptuit INDiGO™, a proprietary platform designed to speed the time required to advance a molecule from discovery into first-in-man studies

Industry-Leading Customer Service

• Focus on providing industry leading services compliant with regulatory requirements and customer expectations, delivered as promised and led with expert project managers
• Improving customer satisfaction as measured by an increase in Aptuit's net promoter score and through continued implementation of Lean Six Sigma initiative

Continued Nurturing of Talent

• Continue to attract, retain, and nurture the more than 2500 individuals across 18 locations globally that make Aptuit a partner of choice for its customers

"The demand for outsourced clinical services is growing and Aptuit is well positioned to take a leadership role in this evolving market," commented Thierry Amat, chief financial officer at Aptuit. "The continued strong support of Welsh, Carson, Anderson & Stowe and Temasek Holdings has been critical to Aptuit's achievements and has enabled us to build a strong foundation for continued success in the coming years."

About Aptuit

Aptuit, Inc. is a global pharmaceutical services company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide, driven by a deep commitment to client service, quality, and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's largest private equity investors. For more information about Aptuit please visit www.aptuit.com.

SOURCE Aptuit, Inc.